Entyvio 300 MG vials
Ended Awarded Last action
- Contract number
- SPE2DR26FHDC6
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $49,663
Award facts
- Contract value 100% obligated
- $49,662.50 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $49,662.50 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of Entyvio 300 mg vials. The contract, with an ultimate completion date of February 4, 2026, was issued without a set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. DMS Pharmaceutical Group is a critical supplier within the federal pharmaceutical supply chain and has maintained System for Award Management registration since July 2001.
This delivery order is issued under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion acquisition strategy that establishes multiple regional prime vendor contractors. The underlying indefinite delivery contract, designated SPE2DR and valued at $499,999,999, was awarded on November 13, 2025, and authorizes the issuance of firm fixed-price delivery orders for a comprehensive range of pharmaceutical products to support Department of Defense military healthcare facility operations worldwide through December 31, 2036. The contract structure includes a 30-month base period with three 30-month option periods, positioning DMS Pharmaceutical Group as a key pharmaceutical supplier for global military medical operations.
Quick answers
Who was awarded contract SPE2DR26FHDC6?
SPE2DR26FHDC6 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on February 3, 2026.
How much is contract SPE2DR26FHDC6 worth?
The government has obligated $49,663 on SPE2DR26FHDC6.
Is contract SPE2DR26FHDC6 an order under another contract?
Yes. SPE2DR26FHDC6 is a delivery order under SPE2DR25D9207, an indefinite delivery contract.
Was contract SPE2DR26FHDC6 competed?
The extent of competition for SPE2DR26FHDC6 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award